// App-Quantinova.ai

506 : Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: FINCH1 Primary Outcome Results

Researchers

Presenter

  • Alan Kivitz

Principal Investigators

  • Yoshiya Tanaka

  • Desiree van der Heijde

  • Franziska Matzkies

  • Beatrix Bartok

  • Lei Ye

  • Ying Guo

  • Chantal Tasset

  • John Sundy

  • Neelufar Mozaffarian

  • Robert B.M. Landewe

  • Sang-Cheol Bae

  • Edward Keystone

  • Peter Nash

Medical Centers

  • CHU Montpellier, Montpellier University, Montpellier, France

  • Altoona Center for Clinical Research, Duncansville, PA

  • University of Occupational and Environmental Health, Kitakyushu, Japan

  • Leiden University Medical Centre, Leiden, Netherlands

  • Gilead Sciences, Inc., Foster City, CA

  • Galapagos, Mechelen, Belgium

  • VU University Medical Center, Amsterdam, Netherlands

  • Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea

  • Toronto General Hospital, University of Toronto, Toronto, ON, Canada

  • University of Queensland, Queensland, Australia

Locations

  • France

  • United States

  • Japan

  • Netherlands

  • Belgium

  • Canada

  • Australia

  • Republic of South Korea

Companies

  • Gilead Sciences, Inc

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • Methotrexate

  • Adalimumab

  • Filgotinib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Superiority

  • Active Comparator

  • Non Inferiority

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved